Related Experiment Videos
Ciclopiroxolamine: clinical and microbiological considerations. Preliminary data.
Chemioterapia : International Journal of the Mediterranean Society of Chemotherapy
|February 1, 1986
Summary
Ciclopiroxolamine demonstrated antifungal efficacy in dermatophytosis treatment. While minimum inhibitory concentrations remained stable, clinical improvement was observed in most patients, with excellent drug tolerance.
Area of Science:
- Dermatology
- Mycology
- Pharmacology
Background:
- Dermatophytosis is a common fungal infection requiring effective treatment.
- Ciclopiroxolamine is an antifungal agent with potential therapeutic applications.
Purpose of the Study:
- To evaluate the clinical efficacy and in vitro antifungal activity of ciclopiroxolamine.
- To assess the drug's effect on fungal strains causing dermatophytosis.
Main Methods:
- In vitro minimum inhibitory concentrations (MIC) were determined at baseline (To), day 4 (T4), and day 7 (T7).
- Twenty patients with dermatophytosis were treated with ciclopiroxolamine for 7 days.
- Clinical outcomes and drug tolerance were assessed.
Main Results:
- No significant variations in MIC values were observed throughout the treatment period.
- High linear correlation coefficients (0.93 for T4 vs. To, 1.0 for T7 vs. T4) indicated stable antifungal activity.
- Clinical improvement was noted in 16 out of 20 patients (5 recovered, 11 improved).
- Drug tolerance was excellent in 19 out of 20 patients.
Conclusions:
- Ciclopiroxolamine exhibits stable in vitro antifungal activity against dermatophytes.
- The drug demonstrates clinical efficacy in treating dermatophytosis, with a high rate of improvement and good tolerance.